An anti-ROS/hepatic fibrosis drug delivery system based on salvianolic acid B loaded mesoporous silica nanoparticles

Qianjun He; Jiamin Zhang; Feng Chen; Limin Guo; Ziyan Zhu; Jianlin Shi

doi:10.1016/j.biomaterials.2010.07.008

An anti-ROS/hepatic fibrosis drug delivery system based on salvianolic acid B loaded mesoporous silica nanoparticles

Qianjun He
, Jiamin Zhang
, Feng Chen
, Limin Guo
, Ziyan Zhu
, Jianlin Shi^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

140 Scopus citations

Abstract

The rhodamine B (RhB) covalently grafted SBA-15-structured mesoporous silica nanoparticles (MSNs-RhB) of high surface area (750 m² g^-1), large pore volume (0.7 cm³ g^-1), uniform particle size (about 400 nm) and positively charged surface (29.6 ± 5.0 mV), has been developed as a drug delivery system (SAB@MSNs-RhB) for anti-ROS (reactive oxygen species)/hepatic fibrosis by loading a negatively charged drug salvianolic acid B (SAB). The dosage formulation SAB@MSNs-RhB effectively protected the loaded drug SAB from decomposition. The multi-release experimental results showed that SAB@MSNs-RhB exhibited an outstanding SAB sustained-release property, and relatively high SAB release rates and concentrations in a long term after the consumption of previously released SAB as compared to SAB loaded MSNs (SAB@MSNs) of negatively charged surface (-31.1 ± 2.6 mV). The influences of the drug concentration, incubation time, drug formula and drug carrier on the ROS level, proliferative activity and cytotoxicity of LX-2 cells were evaluated. The results showed that the inhibiting effect of SAB@MSNs-RhB on the ROS level and proliferative activity of LX-2 cells was more remarkable than free SAB in a long term (72 h), and became more intensive with the increase of the sample concentration and the incubation time. SAB@MSNs-RhB enhanced the cellular drug uptake, the drug bioaccessability and efficacy for anti-ROS/hepatic fibrosis via the nanoparticles-mediated endocytosis and the sustained release of the drug. There was no visible cytotoxicity of free SAB, MSNs-RhB and SAB@MSNs-RhB against LX-2 cells in a broad concentration range (0.5-100 μm) and incubation time periods up to 72 h. The blood compatibility of the carrier MSNs-RhB was evaluated by investigating the hemolysis and coagulation behaviors in a broad concentration range (50-500 μg mL^-1) under in vitro conditions. The results suggested that MSNs-RhB possessed good blood compatibility.

Original language	English
Pages (from-to)	7785-7796
Number of pages	12
Journal	Biomaterials
Volume	31
Issue number	30
DOIs	https://doi.org/10.1016/j.biomaterials.2010.07.008
State	Published - Oct 2010
Externally published	Yes

Keywords

Anti-hepatic fibrosis
Blood compatibility
Drug release
Mesoporous silica
Nanoparticle
Salvianolic acid

Access to Document

10.1016/j.biomaterials.2010.07.008

Cite this

@article{4b689be5ae0b4ab8b2c0136e7d2a1061,

title = "An anti-ROS/hepatic fibrosis drug delivery system based on salvianolic acid B loaded mesoporous silica nanoparticles",

abstract = "The rhodamine B (RhB) covalently grafted SBA-15-structured mesoporous silica nanoparticles (MSNs-RhB) of high surface area (750 m2 g-1), large pore volume (0.7 cm3 g-1), uniform particle size (about 400 nm) and positively charged surface (29.6 ± 5.0 mV), has been developed as a drug delivery system (SAB@MSNs-RhB) for anti-ROS (reactive oxygen species)/hepatic fibrosis by loading a negatively charged drug salvianolic acid B (SAB). The dosage formulation SAB@MSNs-RhB effectively protected the loaded drug SAB from decomposition. The multi-release experimental results showed that SAB@MSNs-RhB exhibited an outstanding SAB sustained-release property, and relatively high SAB release rates and concentrations in a long term after the consumption of previously released SAB as compared to SAB loaded MSNs (SAB@MSNs) of negatively charged surface (-31.1 ± 2.6 mV). The influences of the drug concentration, incubation time, drug formula and drug carrier on the ROS level, proliferative activity and cytotoxicity of LX-2 cells were evaluated. The results showed that the inhibiting effect of SAB@MSNs-RhB on the ROS level and proliferative activity of LX-2 cells was more remarkable than free SAB in a long term (72 h), and became more intensive with the increase of the sample concentration and the incubation time. SAB@MSNs-RhB enhanced the cellular drug uptake, the drug bioaccessability and efficacy for anti-ROS/hepatic fibrosis via the nanoparticles-mediated endocytosis and the sustained release of the drug. There was no visible cytotoxicity of free SAB, MSNs-RhB and SAB@MSNs-RhB against LX-2 cells in a broad concentration range (0.5-100 μm) and incubation time periods up to 72 h. The blood compatibility of the carrier MSNs-RhB was evaluated by investigating the hemolysis and coagulation behaviors in a broad concentration range (50-500 μg mL-1) under in vitro conditions. The results suggested that MSNs-RhB possessed good blood compatibility.",

keywords = "Anti-hepatic fibrosis, Blood compatibility, Drug release, Mesoporous silica, Nanoparticle, Salvianolic acid",

author = "Qianjun He and Jiamin Zhang and Feng Chen and Limin Guo and Ziyan Zhu and Jianlin Shi",

year = "2010",

month = oct,

doi = "10.1016/j.biomaterials.2010.07.008",

language = "英语",

volume = "31",

pages = "7785--7796",

journal = "Biomaterials",

issn = "0142-9612",

publisher = "Elsevier Ltd",

number = "30",

}

TY - JOUR

T1 - An anti-ROS/hepatic fibrosis drug delivery system based on salvianolic acid B loaded mesoporous silica nanoparticles

AU - He, Qianjun

AU - Zhang, Jiamin

AU - Chen, Feng

AU - Guo, Limin

AU - Zhu, Ziyan

AU - Shi, Jianlin

PY - 2010/10

Y1 - 2010/10

N2 - The rhodamine B (RhB) covalently grafted SBA-15-structured mesoporous silica nanoparticles (MSNs-RhB) of high surface area (750 m2 g-1), large pore volume (0.7 cm3 g-1), uniform particle size (about 400 nm) and positively charged surface (29.6 ± 5.0 mV), has been developed as a drug delivery system (SAB@MSNs-RhB) for anti-ROS (reactive oxygen species)/hepatic fibrosis by loading a negatively charged drug salvianolic acid B (SAB). The dosage formulation SAB@MSNs-RhB effectively protected the loaded drug SAB from decomposition. The multi-release experimental results showed that SAB@MSNs-RhB exhibited an outstanding SAB sustained-release property, and relatively high SAB release rates and concentrations in a long term after the consumption of previously released SAB as compared to SAB loaded MSNs (SAB@MSNs) of negatively charged surface (-31.1 ± 2.6 mV). The influences of the drug concentration, incubation time, drug formula and drug carrier on the ROS level, proliferative activity and cytotoxicity of LX-2 cells were evaluated. The results showed that the inhibiting effect of SAB@MSNs-RhB on the ROS level and proliferative activity of LX-2 cells was more remarkable than free SAB in a long term (72 h), and became more intensive with the increase of the sample concentration and the incubation time. SAB@MSNs-RhB enhanced the cellular drug uptake, the drug bioaccessability and efficacy for anti-ROS/hepatic fibrosis via the nanoparticles-mediated endocytosis and the sustained release of the drug. There was no visible cytotoxicity of free SAB, MSNs-RhB and SAB@MSNs-RhB against LX-2 cells in a broad concentration range (0.5-100 μm) and incubation time periods up to 72 h. The blood compatibility of the carrier MSNs-RhB was evaluated by investigating the hemolysis and coagulation behaviors in a broad concentration range (50-500 μg mL-1) under in vitro conditions. The results suggested that MSNs-RhB possessed good blood compatibility.

AB - The rhodamine B (RhB) covalently grafted SBA-15-structured mesoporous silica nanoparticles (MSNs-RhB) of high surface area (750 m2 g-1), large pore volume (0.7 cm3 g-1), uniform particle size (about 400 nm) and positively charged surface (29.6 ± 5.0 mV), has been developed as a drug delivery system (SAB@MSNs-RhB) for anti-ROS (reactive oxygen species)/hepatic fibrosis by loading a negatively charged drug salvianolic acid B (SAB). The dosage formulation SAB@MSNs-RhB effectively protected the loaded drug SAB from decomposition. The multi-release experimental results showed that SAB@MSNs-RhB exhibited an outstanding SAB sustained-release property, and relatively high SAB release rates and concentrations in a long term after the consumption of previously released SAB as compared to SAB loaded MSNs (SAB@MSNs) of negatively charged surface (-31.1 ± 2.6 mV). The influences of the drug concentration, incubation time, drug formula and drug carrier on the ROS level, proliferative activity and cytotoxicity of LX-2 cells were evaluated. The results showed that the inhibiting effect of SAB@MSNs-RhB on the ROS level and proliferative activity of LX-2 cells was more remarkable than free SAB in a long term (72 h), and became more intensive with the increase of the sample concentration and the incubation time. SAB@MSNs-RhB enhanced the cellular drug uptake, the drug bioaccessability and efficacy for anti-ROS/hepatic fibrosis via the nanoparticles-mediated endocytosis and the sustained release of the drug. There was no visible cytotoxicity of free SAB, MSNs-RhB and SAB@MSNs-RhB against LX-2 cells in a broad concentration range (0.5-100 μm) and incubation time periods up to 72 h. The blood compatibility of the carrier MSNs-RhB was evaluated by investigating the hemolysis and coagulation behaviors in a broad concentration range (50-500 μg mL-1) under in vitro conditions. The results suggested that MSNs-RhB possessed good blood compatibility.

KW - Anti-hepatic fibrosis

KW - Blood compatibility

KW - Drug release

KW - Mesoporous silica

KW - Nanoparticle

KW - Salvianolic acid

UR - https://www.scopus.com/pages/publications/77955770984

U2 - 10.1016/j.biomaterials.2010.07.008

DO - 10.1016/j.biomaterials.2010.07.008

M3 - 文章

C2 - 20674009

AN - SCOPUS:77955770984

SN - 0142-9612

VL - 31

SP - 7785

EP - 7796

JO - Biomaterials

JF - Biomaterials

IS - 30

ER -

An anti-ROS/hepatic fibrosis drug delivery system based on salvianolic acid B loaded mesoporous silica nanoparticles

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this